Pain in experimental autoimmune encephalitis: A comparative study between different mouse models

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Lu, Jianning ^a   Kurejova, Martina ^a   Wirotanseng, Laura N ^a   Linker, Ralf A ^b   Kuner, Rohini ^a   Tappe Theodor, Anke ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; ALLODYNIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MOUSE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROCHEMISTRY; NOCICEPTION; NONHUMAN; PAIN; PERIPHERAL NERVE;

EID: 84866984012     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-233     Document Type: Article

References (96)

1. Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol 1984, 41:1270-1272. 10.1001/archneur.1984.04050230052017, 6208884.
2. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study. Ital J Neurol Sci 1995, 16:629-632. 10.1007/BF02230913, 8838789.
3. Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol 2003, 60:1089-1094. 10.1001/archneur.60.8.1089, 12925364.
4. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991, 84:197-200.
5. Pöllmann W, Feneberg W, Erasmus LP. Pain in multiple sclerosis-a still underestimated problem. The 1 year prevalence of pain syndromes, significance and quality of care of multiple sclerosis inpatients. Nervenarzt 2004, 75:135-140. 10.1007/s00115-003-1656-5, 14770283.
6. Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain 2007, 127:35-41. 10.1016/j.pain.2006.07.015, 16949751.
7. Kenner M, Menon U, Elliott DG. Multiple sclerosis as a painful disease. Int Rev Neurobiol 2007, 79:303-321.
8. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis-prevalence and clinical characteristics. Eur J Pain 2005, 9:531-542. 10.1016/j.ejpain.2004.11.005, 16139182.
9. Svendsen KB, Jensen TS, Hansen HJ, Bach FW. Sensory function and quality of life in patients with multiple sclerosis and pain. Pain 2005, 114:473-481. 10.1016/j.pain.2005.01.015, 15777872.
10. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol 1994, 36(Suppl):S47-53.
11. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971. 10.1093/brain/awl075, 16632554.
12. Kuerten S, Angelov DN. Comparing the CNS morphology and immunobiology of different EAE models in C57BL/6 mice - a step towards understanding the complexity of multiple sclerosis. Ann Anat 2008, 190:1-15. 10.1016/j.aanat.2007.11.001, 18342137.
13. Berger T, Weerth S, Kojima K, Linington C, Wekerle H, Lassmann H. Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997, 76:355-364.
14. Schmidt S. Candidate autoantigens in multiple sclerosis. Mult Scler 1999, 5:147-160.
15. Aicher SA, Silverman MB, Winkler CW, Bebo BF. Hyperalgesia in an animal model of multiple sclerosis. Pain 2004, 110:560-570. 10.1016/j.pain.2004.03.025, 15288396.
16. Olechowski CJ, Truong JJ, Kerr BJ. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain 2009, 141:156-164. 10.1016/j.pain.2008.11.002, 19084337.
17. Rodrigues DH, Sachs D, Teixeira AL. Mechanical hypernociception in experimental autoimmune encephalomyelitis. Arq Neuropsiquiatr 2009, 67:78-81. 10.1590/S0004-282X2009000100019, 19330217.
18. Lisi L, Navarra P, Cirocchi R, Sharp A, Stigliano E, Feinstein DL, Dello Russo C. Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis. J Neuroimmunol 2012, 243:43-51. 10.1016/j.jneuroim.2011.12.018, 22264993.
19. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002, 8:620-624. 10.1038/nm0602-620, 12042814.
20. Stösser S, Agarwal N, Tappe-Theodor A, Yanagisawa M, Kuner R. Dissecting the functional significance of endothelin A receptors in peripheral nociceptors in vivo via conditional gene deletion. Pain 2010, 148:206-214. 10.1016/j.pain.2009.09.024, 19879049.
21. Tappe-Theodor A, Constantin CE, Tegeder I, Lechner SG, Langeslag M, Lepcynzsky P, Wirotanseng RI, Kurejova M, Agarwal N, Nagy G, et al. Galpha(q/11) signaling tonically modulates nociceptor function and contributes to activity-dependent sensitization. Pain 2012, 153:184-196.
22. Jiao Y, Sun Z, Lee T, Fusco FR, Kimble TD, Meade CA, Cuthbertson S, Reiner A. A simple and sensitive antigen retrieval method for free-floating and slide-mounted tissue sections. J Neurosci Methods 1999, 93:149-162. 10.1016/S0165-0270(99)00142-9, 10634500.
23. Kim KK, Adelstein RS, Kawamoto S. Identification of neuronal nuclei (NeuN) as Fox-3, a new member of the Fox-1 gene family of splicing factors. J Biol Chem 2009, 284:31052-31061. 10.1074/jbc.M109.052969, 2781505, 19713214.
24. Portiansky EL, Barbeito CG, Gimeno EJ, Zuccolilli GO, Goya RG. Loss of NeuN immunoreactivity in rat spinal cord neurons during aging. Exp Neurol 2006, 202:519-521. 10.1016/j.expneurol.2006.07.014, 16935281.
25. Unal-Cevik I, Kilinc M, Gursoy-Ozdemir Y, Gurer G, Dalkara T. Loss of NeuN immunoreactivity after cerebral ischemia does not indicate neuronal cell loss: a cautionary note. Brain Res 2004, 1015:169-174. 10.1016/j.brainres.2004.04.032, 15223381.
26. Streit WJ, Kreutzberg GW. Lectin binding by resting and reactive microglia. J Neurocytol 1987, 16:249-260. 10.1007/BF01795308, 3625239.
27. O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008, 137:96-111. 10.1016/j.pain.2007.08.024, 17928147.
28. Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008, 22:291-324. 10.2165/00023210-200822040-00003, 18336059.
29. Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, Murray TJ. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 1994, 58:89-93. 10.1016/0304-3959(94)90188-0, 7970843.
30. Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005, 11:322-327. 10.1191/1352458505ms1168oa, 15957515.
31. Solaro C, Brichetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, Gasperini C, Ghezzi A, Martinelli V, Milanese C, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004, 63:919-921. 10.1212/01.WNL.0000137047.85868.D6, 15365151.
32. Ehde DM, Osborne TL, Hanley MA, Jensen MP, Kraft GH. The scope and nature of pain in persons with multiple sclerosis. Mult Scler 2006, 12:629-638. 10.1177/1352458506071346, 17086910.
33. Grasso MG, Clemenzi A, Tonini A, Pace L, Casillo P, Cuccaro A, Pompa A, Troisi E. Pain in multiple sclerosis: a clinical and instrumental approach. Mult Scler 2008, 14:506-513. 10.1177/1352458507085553, 18562505.
34. Hirsh AT, Turner AP, Ehde DM, Haselkorn JK. Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil 2009, 90:646-651. 10.1016/j.apmr.2008.10.019, 3034239, 19345781.
35. Michalski D, Liebig S, Thomae E, Hinz A, Bergh FT. Pain in patients with multiple sclerosis: a complex assessment including quantitative and qualitative measurements provides for a disease-related biopsychosocial pain model. J Pain Res 2011, 4:219-225. 3160835, 21887119.
36. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology 1988, 38:1830-1834. 10.1212/WNL.38.12.1830, 2973568.
37. Osborne TL, Jensen MP, Ehde DM, Hanley MA, Kraft G. Psychosocial factors associated with pain intensity, pain-related interference, and psychological functioning in persons with multiple sclerosis and pain. Pain 2007, 127:52-62. 10.1016/j.pain.2006.07.017, 16950570.
38. Garbay B, Heape AM, Sargueil F, Cassagne C. Myelin synthesis in the peripheral nervous system. Prog Neurobiol 2000, 61:267-304. 10.1016/S0301-0082(99)00049-0, 10727776.
39. Liu H, Shiryaev SA, Chernov AV, Kim Y, Shubayev I, Remacle AG, Baranovskaya S, Golubkov VS, Strongin AY, Shubayev VI. Immunodominant fragments of myelin basic protein initiate T cell-dependent pain. J Neuroinflammation 2012, 9:119. 10.1186/1742-2094-9-119, 3416717, 22676642.
40. Moalem-Taylor G, Allbutt HN, Iordanova MD, Tracey DJ. Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy. Brain Behav Immun 2007, 21:699-710. 10.1016/j.bbi.2006.07.007, 17005365.
41. D'Amelio FE, Smith ME, Eng LF. Sequence of tissue responses in the early stages of experimental allergic encephalomyelitis (EAE): immunohistochemical, light microscopic, and ultrastructural observations in the spinal cord. Glia 1990, 3:229-240. 10.1002/glia.440030402, 2144503.
42. Gehrmann J, Gold R, Linington C, Lannes-Vieira J, Wekerle H, Kreutzberg GW. Microglial involvement in experimental autoimmune inflammation of the central and peripheral nervous system. Glia 1993, 7:50-59. 10.1002/glia.440070110, 8380791.
43. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 2008, 18:86-95. 10.1111/j.1750-3639.2007.00110.x, 18042261.
44. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, Cuzner ML, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002, 125:1462-1473. 10.1093/brain/awf165, 12076997.
45. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl) 1997, 75:165-173.
46. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999, 22:219-240. 10.1146/annurev.neuro.22.1.219, 10202538.
47. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res 2005, 81:302-313. 10.1002/jnr.20562, 15954124.
48. Milligan ED, O'Connor KA, Nguyen KT, Armstrong CB, Twining C, Gaykema RP, Holguin A, Martin D, Maier SF, Watkins LR. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci 2001, 21:2808-2819.
49. Ozenci V, Kouwenhoven M, Link H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult Scler 2002, 8:396-404. 10.1191/1352458502ms837rr, 12356206.
50. Szczucinski A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007, 115:137-146.
51. Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 2007, 3:33. 10.1186/1744-8069-3-33, 2186318, 17974036.
52. Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003, 23:1026-1040.
53. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36. 10.1038/nrn2533, 2752436, 19096368.
54. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002, 82:981-1011.
55. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol 2003, 521:1-21.
56. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998, 86:20-29. 10.1016/S0165-5728(98)00002-2, 9655469.
57. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998, 84:238-249. 10.1016/S0165-5728(97)00208-7, 9628469.
58. Van Der Voorn P, Tekstra J, Beelen RH, Tensen CP, Van Der Valk P, De Groot CJ. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999, 154:45-51. 10.1016/S0002-9440(10)65249-2, 1853444, 9916917.
59. Fischer FR, Santambrogio L, Luo Y, Berman MA, Hancock WW, Dorf ME. Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression. J Neuroimmunol 2000, 110:195-208. 10.1016/S0165-5728(00)00351-9, 11024550.
60. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000, 192:899-905. 2193286, 10993920.
61. Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, DeMartino JA, MacIntyre DE, Forrest MJ. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A 2003, 100:7947-7952. 10.1073/pnas.1331358100, 164693, 12808141.
62. Dansereau MA, Gosselin RD, Pohl M, Pommier B, Mechighel P, Mauborgne A, Rostene W, Kitabgi P, Beaudet N, Sarret P, Melik-Parsadaniantz S. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem 2008, 106:757-769. 10.1111/j.1471-4159.2008.05429.x, 18419759.
63. Menetski J, Mistry S, Lu M, Mudgett JS, Ransohoff RM, Demartino JA, Macintyre DE, Abbadie C. Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses. Neuroscience 2007, 149:706-714. 10.1016/j.neuroscience.2007.08.014, 17870246.
64. Tanaka T, Minami M, Nakagawa T, Satoh M. Enhanced production of monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in the development of neuropathic pain. Neurosci Res 2004, 48:463-469. 10.1016/j.neures.2004.01.004, 15041200.
65. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, Park JY, Lind AL, Ma Q, Ji RR. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 2009, 29:4096-4108. 10.1523/JNEUROSCI.3623-08.2009, 2682921, 19339605.
66. Thacker MA, Clark AK, Bishop T, Grist J, Yip PK, Moon LD, Thompson SW, Marchand F, McMahon SB. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain 2009, 13:263-272. 10.1016/j.ejpain.2008.04.017, 18554968.
67. Shin BA, Yoo HG, Kim HS, Kim MH, Hwang YS, Chay KO, Lee KY, Ahn BW, Jung YD. P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells. Oncol Rep 2003, 10:1467-1471.
68. Ji RR, Baba H, Brenner GJ, Woolf CJ. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 1999, 2:1114-1119. 10.1038/16040, 10570489.
69. Ma W, Quirion R. Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain 2002, 99:175-184. 10.1016/S0304-3959(02)00097-0, 12237195.
70. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, Decosterd I, Ji RR. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 2006, 26:3551-3560. 10.1523/JNEUROSCI.5290-05.2006, 16571763.
71. Gosselin RD, Varela C, Banisadr G, Mechighel P, Rostene W, Kitabgi P, Melik-Parsadaniantz S. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones. J Neurochem 2005, 95:1023-1034. 10.1111/j.1471-4159.2005.03431.x, 16150057.
72. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291. 10.1002/glia.10108, 12203394.
73. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511. 10.1038/35081571, 11433375.
74. Kieseier BC, Clements JM, Pischel HB, Wells GM, Miller K, Gearing AJ, Hartung HP. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barre syndrome. Ann Neurol 1998, 43:427-434. 10.1002/ana.410430404, 9546322.
75. Nygardas PT, Hinkkanen AE. Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol 2002, 128:245-254. 10.1046/j.1365-2249.2002.01855.x, 1906387, 11985514.
76. Toft-Hansen H, Nuttall RK, Edwards DR, Owens T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 2004, 173:5209-5218.
77. Dong M, Liu R, Guo L, Li C, Tan G. Pathological findings in rats with experimental allergic encephalomyelitis. Apmis 2008, 116:972-984. 10.1111/j.1600-0463.2008.00726.x, 19132994.
78. Ji RR, Xu ZZ, Wang X, Lo EH. Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol Sci 2009, 30:336-340. 10.1016/j.tips.2009.04.002, 2706286, 19523695.
79. Kawasaki Y, Xu ZZ, Wang X, Park JY, Zhuang ZY, Tan PH, Gao YJ, Roy K, Corfas G, Lo EH, Ji RR. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14:331-336. 10.1038/nm1723, 2279180, 18264108.
80. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992, 41:29-34. 10.1016/0165-5728(92)90192-N, 1334098.
81. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999, 122(Pt 2):191-197.
82. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, Miller KM, Hauser SL, Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998, 121(Pt 12):2327-2334.
83. Lichtinghagen R, Seifert T, Kracke A, Marckmann S, Wurster U, Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 1999, 99:19-26. 10.1016/S0165-5728(99)00094-6, 10496173.
84. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002, 125:1297-1308. 10.1093/brain/awf133, 12023318.
85. Folgueras AR, Fueyo A, Garcia-Suarez O, Cox J, Astudillo A, Tortorella P, Campestre C, Gutierrez-Fernandez A, Fanjul-Fernandez M, Pennington CJ, et al. Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J Biol Chem 2008, 283:9465-9474. 10.1074/jbc.M709522200, 18245084.
86. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol 2005, 158:213-221. 10.1016/j.jneuroim.2004.09.006, 15589056.
87. Opdenakker G, Nelissen I, Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2003, 2:747-756. 10.1016/S1474-4422(03)00587-8, 14636780.
88. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004, 361:184-187. 10.1016/j.neulet.2003.12.007, 15135924.
89. Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997, 81:255-262. 10.1016/S0306-4522(97)00147-4, 9300418.
90. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 1997, 121:417-424. 10.1038/sj.bjp.0701148, 1564704, 9179382.
91. Kim H, Moon C, Ahn M, Lee Y, Kim S, Matsumoto Y, Koh CS, Kim MD, Shin T. Increased phosphorylation of cyclic AMP response element-binding protein in the spinal cord of Lewis rats with experimental autoimmune encephalomyelitis. Brain Res 2007, 1162:113-120.
92. Misawa S, Kuwabara S, Mori M, Hayakawa S, Sawai S, Hattori T. Peripheral nerve demyelination in multiple sclerosis. Clin Neurophysiol 2008, 119:1829-1833. 10.1016/j.clinph.2008.04.010, 18495530.
93. Sarova-Pinhas I, Achiron A, Gilad R, Lampl Y. Peripheral neuropathy in multiple sclerosis: a clinical and electrophysiologic study. Acta Neurol Scand 1995, 91:234-238. 10.1111/j.1600-0404.1995.tb06996.x, 7625146.
94. Pender MP, Sears TA. Involvement of the dorsal root ganglion in acute experimental allergic encephalomyelitis in the Lewis rat. A histological and electrophysiological study. J Neurol Sci 1986, 72:231-242. 10.1016/0022-510X(86)90011-0, 3486944.
95. Pender MP, Sears TA. Vulnerability of the dorsal root ganglion in experimental allergic encephalomyelitis. Clin Exp Neurol 1985, 21:211-223.
96. Pender MP, Sears TA. The pathophysiology of acute experimental allergic encephalomyelitis in the rabbit. Brain 1984, 107(Pt 3):699-726.